0 participants
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-03-10
- Start Date:
- 2019-12-02
- Completion:
- 2021-11-19
Conditions
- Blasts Under 5 Percent of Peripheral Blood White Cells
- Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level
- IDH2 Gene Mutation
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- DRUG
- PROCEDURE
No Results Yet